Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q4 2024 Earnings Results & Report

Cardiol Therapeutics logo
$0.98 -0.02 (-2.10%)
Closing price 03:59 PM Eastern
Extended Trading
$0.98 +0.01 (+0.61%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiol Therapeutics beat analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.07 versus the -$0.08 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Cardiol Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardiol Therapeutics Q4 2024 Earnings FAQ

Cardiol Therapeutics (NASDAQ:CRDL) reported earnings of -$0.07 per share for Q4 2024, beating the consensus estimate of -$0.08. The report was announced on Monday, March 31, 2025.

Cardiol Therapeutics Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart.

The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure. These candidates are experimental and are not approved medicines.

View Cardiol Therapeutics Profile